Active substance   ravulizumab
Holder     Alexion Pharma Belgium
Status Running
Indication treatment of Paroxysmal Nocturnal Haemoglobinuria in patients who completed the Open Label Extensions of the phase III studies ALXN1210-PNH-301 (EudraCT Nr: 2016-002025-11) or ALXN1210-PNH-303 (EudraCT Nr: 2017-002370-39)           
Public documents Approbation
  Information for the patient
  Informed consent
Last update 02/02/2023


Last updated on 30/05/2023